519 OR641 is a novel dual antagonist antibody that targets LILRB1 and LILRB2 inhibitory receptors and promotes a Th1-like immune response by Peter Probst, Kevin Green, Huyen Dinh, Francisco Zapata, Darbie Whitman, Tom Graddis, Myriam Bouchlaka, Meghan Zuck, Ray Fox, Tatyana Pisarenko, Elsa L Hay, Gajendra Naika, Jacob Heit, Kamal D Puri

494 OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses by Peter Probst, Kevin Green, Huyen Dinh, Francisco Zapata, Darbie Whitman, Tom Graddis, Meghan Zuck, Ray Fox, Myriam N Bouchlaka, Tatyana Pisarenko, Elsa L Hay, Gajendra Naika, Jacob Heit, Kamal D Puri